4TO Stock Overview
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Mainz Biomed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.61 |
| 52 Week High | US$5.38 |
| 52 Week Low | US$0.60 |
| Beta | 0.28 |
| 1 Month Change | -33.88% |
| 3 Month Change | -32.56% |
| 1 Year Change | -87.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4TO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.3% | -3.2% | 2.0% |
| 1Y | -87.9% | -25.4% | 5.9% |
Return vs Industry: 4TO underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 4TO underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 4TO volatility | |
|---|---|
| 4TO Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4TO's share price has been volatile over the past 3 months.
Volatility Over Time: 4TO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 68 | Guido Baechler | mainzbiomed.com |
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Mainz Biomed N.V. Fundamentals Summary
| 4TO fundamental statistics | |
|---|---|
| Market cap | €13.41m |
| Earnings (TTM) | -€24.41m |
| Revenue (TTM) | €831.18k |
16.1x
P/S Ratio-0.5x
P/E RatioIs 4TO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4TO income statement (TTM) | |
|---|---|
| Revenue | US$895.48k |
| Cost of Revenue | US$385.82k |
| Gross Profit | US$509.66k |
| Other Expenses | US$26.81m |
| Earnings | -US$26.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 56.91% |
| Net Profit Margin | -2,936.50% |
| Debt/Equity Ratio | 183.6% |
How did 4TO perform over the long term?
See historical performance and comparison